Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of six systematic review(s)/meta-analysis(es). ^[1-6]
• Cardiac Function in duchenne muscular dystrophy (DMD): High-quality evidence shows that deflazacort is associated with preserved left ventricular ejection fraction (LVEF) and improved fractional shortening (FS). Low-quality evidence suggests deflazacort, prednisone, and prednisolone are linked to improved ejection fraction (EF) and reduced risks of cardiomyopathy, ventricular dysfunction, and heart failure-related mortality.
• Motor Function in DMD: Deflazacort provides superior motor function outcomes compared to prednisone/prednisolone, with significant improvements in 6-minute walk distance (6MWD), 4-stair climb, and 4-stair descend over 48 weeks. Vamorolone 6 mg/kg/day improved motor function compared to the 2 mg/kg/day dose, with notable improvements in time to stand from supine velocity (TTSTANDV), time to run/walk 10 m velocity (TTRWV), 6-min walk test (6MWT), and time to climb 4 stairs velocity (TTCLIMBV).
• There is no safety information available in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.